bioRxivCancer Biology
SAMHD1 limits the efficacy of forodesine in leukaemia by protecting cells against cytotoxicity of dGTP
T. Davenne, J. Klintman, S. Sharma, R. E. Rigby, C. Cursi, A. Bridgeman, B. Dadonaite, K. De Keersmaecker, P. Hillmen, A. Chabes, A. Schuh, J. Rehwinkel
Abstract
The anti-leukaemia agent forodesine causes cytotoxic overload of intracellular deoxyguanosine triphosphate (dGTP) but is efficacious only in a subset of patients. We report that SAMHD1, a phosphohydrolase degrading deoxyribonucleoside triphosphates (dNTPs), protected cells against the effects of dNTP imbalances. SAMHD1-deficient cells induced intrinsic apoptosis upon provision of deoxyribonucleosides, particularly deoxyguanosine (dG). Moreover, dG and forodesine acted synergistically to kill cells lacking SAMHD1. Using mass cytometry, we found that these compounds killed SAMHD1-deficient malignant cells from patients with chronic lymphocytic leukaemia (CLL). Normal cells and CLL cells from patients without SAMHD1 mutation were unaffected. We therefore propose to use forodesine as a precision medicine for leukaemia, stratifying patients by SAMHD1 genotype or expression. O_FIG O_LINKSMALLFIG WIDTH=195 HEIGHT=200 SRC="FIGDIR/small/951517v1_ufig1.gif" ALT="Figure 1"> View larger version (38K): org.highwire.dtl.DTLVardef@69c367org.highwire.dtl.DTLVardef@19be007org.highwire.dtl.DTLVardef@91156corg.highwire.dtl.DTLVardef@1158ec6_HPS_FORMAT_FIGEXP M_FIG O_FLOATNOSupplementary Figure 5.C_FLOATNO Graphical Abstract C_FIG Highlights O_LISAMHD1-deficient cells die upon exposure to deoxyribonucleosides (dNs) C_LIO_LIDeoxyguanosine (dG) is the most toxic dN, inducing apoptosis in cells lacking SAMHD1 C_LIO_LISAMHD1-mutated leukaemic cells can be killed by dG and the PNP-inhibitor forodesine C_LI In BriefSAMHD1 degrades deoxyribonucleoside triphosphates (dNTPs), the building blocks of DNA. Davenne et al. found that SAMHD1 protects cells against dNTP imbalances. Exposure of SAMHD1-deficient cells to deoxyguanosine (dG) results in increased intracellular dGTP levels and subsequent apoptosis. This can be exploited to selectively kill cancer cells that acquired SAMHD1 mutations.
- organism: human
- assay: proteomics
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- SAMHD1 controls nucleoside-based cancer therapeutics, deoxyguanosine toxicity, and inflammation
M. D. Moore, E. Johnson, … W. S. James·bioRxiv·Aug 25, 2022
- Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells
T. Rothenburger, D. Thomas, … J. Cinatl·bioRxiv·Jul 19, 2021
- The Synergism Between DHODH Inhibitors and Dipyridamole Leads to Metabolic Lethality in Acute Myeloid Leukemia
V. Gaidano, M. Houshmand, … P. Circosta·bioRxiv·Oct 10, 2020
- Defective Nucleotide Catabolism Defines a Subset of Cancers Sensitive to Purine Nucleoside Phosphorylase Inhibition
E. R. Abt, V. Lok, … C. G. Radu·bioRxiv·Nov 4, 2019
- Pharmacological inhibition of LSD1 triggers myeloid differentiation by targeting GSE1, a novel oncogene in AML
L. Nicosia, F. L. Boffo, … T. Bonaldi·bioRxiv·Feb 16, 2021
- Succinate Dehydrogenase-Deficient Cancer Cells Have Increased Susceptibility to Ym155 Induced DNA Damage
Qianjin Guo, Sooyeon Lee, … Justin P. Annes·Endocrine Related CancerPeer-reviewed·Feb 19, 2026